# Immix Biopharma (IMMX) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/IMMX
## Company Profile
- Ticker: IMMX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology
## Stock Data
- Close: 13.25 USD
- Market cap: 595503940.115 USD
- Last updated: 2026-09-08
## Business Overview
Immix Biopharma is a biotechnology company focused on immune-driven therapies and oncology programs. Its strategy centers on translating immune biology into targeted treatment options.
## Why The Stock Is Moving

As of Sep 8, 2026, IMMX closed down 4.74% at $13.25. No new same-company headline was identified in the current news window.

## Geographic Base

Headquartered in the United States and listed on NASDAQ, Immix sits in specialty biotechnology.

## Business Model

The company depends on clinical data, platform validation, and the ability to build a differentiated cancer story.

## Landscape Position

Immix is a catalyst-sensitive biotech name whose stock depends on early clinical progress.

## Future Catalysts

- Immix’s catalysts are the oncology and immunology pipeline, especially any update that shows the company can still generate a clearer clinical path. The story remains early and data-dependent.

## Recent News
- 2026-08-04 14:15 EST — [Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference](https://biopharmsignal.com/news/IMMX/immix-biopharma-to-participate-in-the-morgan-stanley-24th-annual-global-healthca-f710644e) — Source: Immix Biopharma
- 2026-05-22 22:15 EST — [Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock](https://biopharmsignal.com/news/IMMX/immix-biopharma-announces-closing-of-150-million-underwritten-offering-of-common-fbf30fd8) — Source: Immix Biopharma
- 2026-05-21 11:30 EST — [Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock](https://biopharmsignal.com/news/IMMX/immix-biopharma-announces-pricing-of-150-million-underwritten-offering-of-common-15fc60bd) — Source: Immix Biopharma
- 2026-05-21 11:00 EST — [Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2](https://biopharmsignal.com/news/IMMX/immix-biopharma-announces-95-complete-response-rate-in-interim-update-from-relap-603927c0) — Source: Immix Biopharma
- 2026-04-09 13:45 EST — [Immix Biopharma to Participate in the Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/IMMX/immix-biopharma-to-participate-in-the-jefferies-global-healthcare-conference-39e654b7) — Source: Immix Biopharma